US EPA

724828 

Journal Article 

Anxiolytic efficacy and tolerance of tetrabamate in anxious alcoholics: Multicentric double blind study versus placebo Efficacite anxiolytique et tolerance du tetrabamate chez des patients anxieux abusant de l'alcool. Etude multicentrique en double insu contre placebo 

Loo, H; Guelfi, JD; Malka, R 

1986 

12/5 (291-297) 

The anxiolytic efficacy of tetrabamate was evaluated in 68 out-patients presenting an anxiety state with alcohol abuse according to DSM III criteria. The study followed a double-blind placebo-controlled design with parallel groups and lasted for 21 days. Anxiety was evaluated by the Hamilton anxiety scale, Norris visual analog scales, and the Hopkins Symptom Check List, along with the investigator's assessment. Safety was evaluated in terms of somatic symptoms (CHESS 84) and the physician's overall evaluation. The anxiolytic activity of tetrabamate (three 300 mg tablets/day) was significantly greater than that of placebo from the seventh day on. There were no statistically significant differences in the safety profile between tetrabamate and placebo. Moreover, in the tetrabamate group the significantly greater improvement in the scores of somatic symptoms indicates that the compound caused no notable adverse effects 

difebarbamate